• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Neurocrine Biosciences, Inc. - Common Stock (NQ: NBIX )

    139.44 +0.41 (+0.29%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Neurocrine Biosciences, Inc. - Common Stock

    New Study Reveals How Classical Music Could Revolutionize Depression Care
    In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
    Via PressReach
    Exposures Product Safety
    Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
    From Sentia Medical Sciences, Inc.
    Via GlobeNewswire
    The 5 Stocks Most Sold By Insiders This Year
    Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices. 
    Via MarketBeat
    Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
    Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
    Via MarketBeat
    Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
    From Sentia Medical Sciences, Inc.
    Via GlobeNewswire
    Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
    Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
    Via MarketBeat
    Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
    Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
    Via MarketBeat
    Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
    Via AB Newswire
    Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
    Via FinancialNewsMedia
    Biotechs Aligning to Address Challenges for Developing Therapeutics for Billion Dollar Neurological Disorders Industry
    Via FinancialNewsMedia
    Exposures COVID-19
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.